Neurim Pharmaceuticals (1991) Ltd.

Sleep Medicine

Research activity is centered on sleep disorders, with a specific focus on idiopathic Rapid Eye Movement Behavior Disorder and related disturbances of sleep architecture and nocturnal motor control.

  • Rapid Eye Movement Behavior Disorder
  • Sleep laboratory evaluation

The sponsor’s clinical interest in this area reflects work aimed at understanding and addressing abnormal behaviors occurring during REM sleep.

Neurology

The sponsor is involved in neurological research linked to disorders that affect sleep regulation and motor inhibition during sleep, with attention to the clinical features of isolated RBD.

  • Neurological sleep disturbances
  • Motor dysregulation during sleep

This area connects clinical investigation of sleep-related neurological symptoms with therapeutic development in a rare neurobehavioral condition.

Therapeutic Development

Clinical research support is directed toward evaluation of piromelatine for its effects on symptoms associated with iRBD, with emphasis on both efficacy and safety in a sleep-disorder setting.

  • Piromelatine
  • Efficacy and safety assessment

The therapeutic emphasis is on pharmacological management of a disorder with limited treatment options in the sleep medicine field.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects and Safety of Piromelatine for Patients with Idiopathic Rapid Eye Movement Behavior Disorder (iRBD)

    Not recruiting

    2 1 1
    Investigated drugs:
    Austria